These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 34331826)
21. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney disease patients. Arogundade FA; Soyinka FO; Sanusi AA; Ojo OE; Akinsola A Niger Postgrad Med J; 2013 Dec; 20(4):299-304. PubMed ID: 24633272 [TBL] [Abstract][Full Text] [Related]
22. Anaemia in diabetic renal failure: is there a role for early erythropoietin treatment in preventing cardiovascular mortality? Abaterusso C; Pertica N; Lupo A; Ortalda V; Gambaro G Diabetes Obes Metab; 2008 Sep; 10(10):843-9. PubMed ID: 18093210 [TBL] [Abstract][Full Text] [Related]
23. Iron therapy for managing anaemia in chronic kidney disease. Macdougall IC Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):358-363. PubMed ID: 29905580 [TBL] [Abstract][Full Text] [Related]
24. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). Park H; Liu X; Henry L; Harman J; Ross EA BMC Nephrol; 2018 Nov; 19(1):318. PubMed ID: 30413150 [TBL] [Abstract][Full Text] [Related]
25. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712 [TBL] [Abstract][Full Text] [Related]
26. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Del Vecchio L; Locatelli F Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639 [TBL] [Abstract][Full Text] [Related]
27. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD; Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437 [TBL] [Abstract][Full Text] [Related]
28. Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease. Yugavathy N; Abdullah BM; Lim SK; Abdul Gafor AHB; Wong MG; Bavanandan S; Wong HS; Huri HZ Curr Issues Mol Biol; 2023 Aug; 45(8):6550-6563. PubMed ID: 37623232 [TBL] [Abstract][Full Text] [Related]
29. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807 [No Abstract] [Full Text] [Related]
30. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. St Peter WL; Guo H; Kabadi S; Gilbertson DT; Peng Y; Pendergraft T; Li S BMC Nephrol; 2018 Mar; 19(1):67. PubMed ID: 29544446 [TBL] [Abstract][Full Text] [Related]
31. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. Sakashita M; Tanaka T; Nangaku M Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411 [TBL] [Abstract][Full Text] [Related]
32. Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents. Io H; Aizawa M; Funabiki K; Horikoshi S; Tomino Y Nephrology (Carlton); 2015 Dec; 20 Suppl 4():7-13. PubMed ID: 26439537 [TBL] [Abstract][Full Text] [Related]
33. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Yap DYH; McMahon LP; Hao CM; Hu N; Okada H; Suzuki Y; Kim SG; Lim SK; Vareesangthip K; Hung CC; Nangaku M; Nephrology (Carlton); 2021 Feb; 26(2):105-118. PubMed ID: 33222343 [TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease? Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498 [TBL] [Abstract][Full Text] [Related]
35. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Maxwell PH; Eckardt KU Nat Rev Nephrol; 2016 Mar; 12(3):157-68. PubMed ID: 26656456 [TBL] [Abstract][Full Text] [Related]
37. Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study. Lamerato L; James G; van Haalen H; Hedman K; Sloand JA; Tang A; Wittbrodt ET; Yee J BMC Nephrol; 2022 Apr; 23(1):166. PubMed ID: 35490226 [TBL] [Abstract][Full Text] [Related]
38. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965 [TBL] [Abstract][Full Text] [Related]
39. Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease. Alexandre AF; Morga A; Thomas C; Krucien N; Tervonen T; Jiletcovici A; Marsh K Adv Ther; 2023 Feb; 40(2):641-657. PubMed ID: 36449257 [TBL] [Abstract][Full Text] [Related]